Rising Star: Mayer Brown's Andrew Calica

Law360, New York (April 2, 2015, 4:12 PM EDT) -- Mayer Brown LLP partner Andrew Calica has secured a string of game-changing victories in litigation implicating branded-drug maker UCB Inc. over alleged neurological disorders caused by its heartburn drug Reglan, landing him a spot among Law360’s Rising Stars list of top attorneys under 40.

In 2009, when the U.S. Food and Drug Administration added a black box warning cautioning users of metoclopramide — the drug contained in Reglan — that usage exceeding 12 weeks could cause neurological problems, Calica was on a team of Mayer Brown...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.